Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
40.79
-1.56 (-3.68%)
At close: Feb 27, 2026, 4:00 PM EST
41.11
+0.32 (0.78%)
After-hours: Feb 27, 2026, 7:22 PM EST

Vera Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
100.224123.7921.9111.92
Research & Development
215.26126.1778.2368.9922.48
Operating Expenses
315.47167.17102.0190.934.4
Operating Income
-315.47-167.17-102.01-90.9-34.4
Interest Expense
--7.63-3.79-0.99-0.02
Interest & Investment Income
-20.717.981.750.02
Other Non Operating Income (Expenses)
15.861.941.831.9-
EBT Excluding Unusual Items
-299.61-152.15-95.99-88.25-34.41
Gain (Loss) on Sale of Investments
----0.81-0.89
Gain (Loss) on Sale of Assets
----2.69
Pretax Income
-299.61-152.15-95.99-89.06-32.61
Income Tax Expense
00000
Net Income
-299.62-152.15-95.99-89.06-32.61
Net Income to Common
-299.62-152.15-95.99-89.06-32.61
Shares Outstanding (Basic)
6455432713
Shares Outstanding (Diluted)
6455432713
Shares Change (YoY)
16.10%29.55%60.73%97.76%4099.14%
EPS (Basic)
-4.66-2.75-2.25-3.35-2.43
EPS (Diluted)
-4.66-2.75-2.25-3.35-2.43
Free Cash Flow
--135.65-92.24-67.66-23.71
Free Cash Flow Per Share
--2.45-2.16-2.55-1.76
EBITDA
-315.03-167.07-101.99-90.73-34.23
D&A For EBITDA
0.440.110.020.180.18
EBIT
-315.47-167.17-102.01-90.9-34.4
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q